Download MendeleyDiscovery of the First Highly Selective and Broadly Effective Macrocycle-Based Type II TRK Inhibitors that Overcome Clinically Acquired Resistance.
Wang, Z., Wang, J., Wang, Y., Xiang, S., Song, X., Tu, Z., Zhou, Y., Zhang, Z.M., Zhang, Z., Ding, K., Lu, X.(2022) J Med Chem 65: 6325-6337
- PubMed: 35426680
- DOI: https://doi.org/10.1021/acs.jmedchem.2c00308
- Primary Citation of Related Structures:
7XAF - PubMed Abstract:
Tropomyosin receptor kinase (TRK) secondary mutations mediating acquired resistance, especially at the solvent-front (SF) and the DFG motif, represent an unmet clinical need. Small-molecule macrocyclic kinase inhibitors have displayed significant advantages in overcoming clinical resistance driven by kinase mutations; however, all reported small-molecule macrocyclic TRK inhibitors are all type I inhibitors and are therefore much more sensitive to SF than xDFG mutations. Novel therapeutics for patients with xDFG resistance mutations are urgently needed. We report the first highly selective macrocycle-based potent type II TRK inhibitor, 7b , that exhibits high inhibitory potency toward various TRK fusion protein variants as well as wild type. 7b exhibited potent antiproliferative activity against Ba/F3 cells harboring CD74-TRKA G667C and ETV6-TRKC G696C with half-maximum inhibitory concentration (IC 50 ) values of 6 and 1.7 nM, respectively. More importantly, 7b also showed potent antiproliferative activity against a panel of SF mutants (IC 50 = 5.6-110 nM) and displayed extraordinary kinome selectivity.
Organizational Affiliation:
International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education (MOE), School of Pharmacy, Jinan University, #855 Xingye Avenue, Guangzhou 510632, China.
